275 related articles for article (PubMed ID: 34454558)
1. Multifocal high-grade glioma radiotherapy safety and efficacy.
Fleischmann DF; Schön R; Corradini S; Bodensohn R; Hadi I; Hofmaier J; Forbrig R; Thon N; Dorostkar M; Belka C; Niyazi M
Radiat Oncol; 2021 Aug; 16(1):165. PubMed ID: 34454558
[TBL] [Abstract][Full Text] [Related]
2. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
3. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
[TBL] [Abstract][Full Text] [Related]
5. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
[TBL] [Abstract][Full Text] [Related]
7. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
[TBL] [Abstract][Full Text] [Related]
8. Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.
Mills D; Horsley P; Venkatasha V; Back M
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):343-352. PubMed ID: 38553362
[TBL] [Abstract][Full Text] [Related]
9. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.
Reynaud T; Bertaut A; Farah W; Thibouw D; Crehange G; Truc G; Vulquin N
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806498. PubMed ID: 30343637
[TBL] [Abstract][Full Text] [Related]
12. CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures.
Oermann E; Collins BT; Erickson KT; Yu X; Lei S; Suy S; Hanscom HN; Kim J; Park HU; Eldabh A; Kalhorn C; McGrail K; Subramaniam D; Jean WC; Collins SP
J Hematol Oncol; 2010 Jun; 3():22. PubMed ID: 20534128
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
[TBL] [Abstract][Full Text] [Related]
15. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
16. Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: Implications for conformal dose-escalation studies.
Tsien C; Gomez-Hassan D; Ten Haken RK; Tatro D; Junck L; Chenevert TL; Lawrence T
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):328-32. PubMed ID: 15890571
[TBL] [Abstract][Full Text] [Related]
17. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
18. Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Fleischmann DF; Unterrainer M; Corradini S; Rottler M; Förster S; la Fougère C; Siepmann T; Schwaiger M; Bartenstein P; Belka C; Albert NL; Niyazi M
PLoS One; 2019; 14(7):e0216111. PubMed ID: 31339892
[TBL] [Abstract][Full Text] [Related]
19. Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.
Ohno M; Miyakita Y; Takahashi M; Yanagisawa S; Tamura Y; Kawauchi D; Kikuchi M; Igaki H; Yoshida A; Satomi K; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2022 May; 17(1):85. PubMed ID: 35505351
[TBL] [Abstract][Full Text] [Related]
20. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]